<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacotherapy for co-occurring schizophrenia and substance use disorder</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacotherapy for co-occurring schizophrenia and substance use disorder</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacotherapy for co-occurring schizophrenia and substance use disorder</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">E Cabrina Campbell, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stanley N Caroff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan C Mann, MD, DLFAPA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2100746531"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Schizophrenia and addiction are both chronic disorders with serious complications, consequences, and costs for individuals and society. Both conditions are associated with poor adherence to treatment and poorer outcomes when the co-occurring disorder is present.</p><p>Some of the symptoms of schizophrenia overlap with symptoms of intoxication, chronic substance use, or withdrawal from alcohol or other drugs. Family history and the temporal relationship of symptoms can help to distinguish patients with a substance use disorder (SUD) alone from co-occurring schizophrenia and SUD.</p><p>Pharmacotherapy of co-occurring schizophrenia and SUD are described here. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and psychosocial interventions for co-occurring schizophrenia and SUD are described separately. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of schizophrenia or SUD individually (not co-occurring) are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7798.html" rel="external">"Co-occurring schizophrenia and substance use disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/89630.html" rel="external">"Co-occurring schizophrenia and substance use disorder: Psychosocial interventions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14804.html" rel="external">"Schizophrenia in adults: Epidemiology and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15774.html" rel="external">"Schizophrenia in adults: Psychosocial management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7796.html" rel="external">"Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7802.html" rel="external">"Cocaine use disorder: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16750.html" rel="external">"Stimulant use disorder: Psychosocial management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106878.html" rel="external">"Stimulant use disorder: Treatment overview"</a>.)</p><p></p><p class="headingAnchor" id="H83733984"><span class="h1">CLINICAL GOALS AND PRINCIPLES</span><span class="headingEndMark"> — </span>The primary long-term goals of treatment for co-occurring schizophrenia and substance use disorder (SUD) are reduced symptoms of schizophrenia, improved role functioning, reduced substance use, and improved quality of life.</p><p>Both SUD and schizophrenia are associated with poor adherence to treatment and poorer outcomes when the co-occurring disorder is present. Nonadherence is the foremost cause of acute psychotic relapse in this population. Relapses should be anticipated. Clinicians should seek to maintain treatment despite periods of active substance use [<a href="#rid1">1</a>].</p><p>The individual treatments and overall complexity of the treatment plan for schizophrenia and SUD must be weighed against the patient's cognitive and self-care capacities, willingness to participate in treatment, capacity for adherence, education, and resources. More intensive protocols may require external support from family, friends, social service agencies, case managers, or other professional caregivers, especially given the fact that patients with schizophrenia are found often among disadvantaged and lower socioeconomic groups [<a href="#rid2">2,3</a>], which are associated with higher rates of and greater resistance to treatments for substance use [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/105343.html" rel="external">"Assertive community treatment for patients with severe mental illness"</a> and  <a class="medical medical_review" href="/d/html/7799.html" rel="external">"Substance use disorders: Determining appropriate level of care for treatment"</a>.)</p><p class="headingAnchor" id="H3412253805"><span class="h2">Integrated treatment</span><span class="headingEndMark"> — </span>We suggest integrated care rather than parallel or sequential care for patients with co-occurring schizophrenia and SUD. Components of integrated treatment include [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of both disorders (schizophrenia and SUD) by the same clinician or clinical team.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multimodal care generally includes pharmacotherapy and one or more psychosocial interventions. (See  <a class="medical medical_review" href="/d/html/89630.html" rel="external">"Co-occurring schizophrenia and substance use disorder: Psychosocial interventions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Collaborative goal setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respectful and empathic treatment of both conditions – Less confrontational than some SUD treatments, we believe that this approach can help foster a strong therapeutic alliance.</p><p></p><p>The availability of integrated care varies widely. Separate systems of care have traditionally provided mental health care versus SUD treatment in the United States and other countries; this continues to be the case in some areas. The availability of integrated treatment can also vary by level of care, such as inpatient, residential, and outpatient settings.</p><p>Clinical trials comparing integrated and parallel treatment for substance use disorders and schizophrenia in patients with both disorders have shown mixed results [<a href="#rid7">7,8</a>]; however, a broad consensus among researchers and clinicians with expertise in the area supports integrated treatment of co-occurring disorders [<a href="#rid9">9,10</a>]. Treatment of mental disorders and SUD in separate health systems and by separate clinical teams had been associated with poor communication and poor coordination of care.</p><p>When integrated treatment is not available, clinicians treating each disorder separately should coordinate care by:</p><p class="bulletIndent1"><span class="glyph">●</span>Agreeing on a common treatment plan</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Communicating regularly to share information about the patient’s clinical status, treatment compliance, substance use, and risk status</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring the clinical status and treatment response of both conditions</p><p></p><p class="headingAnchor" id="H625900459"><span class="h1">SCHIZOPHRENIA</span><span class="headingEndMark"> — </span>Patients with schizophrenia and a co-occurring substance use disorder (SUD) should be stabilized with an antipsychotic medication at the outset of treatment. Sequential treatment of the addiction first and followed later by treatment of schizophrenia is not recommended.</p><p class="headingAnchor" id="H3132735823"><span class="h2">Antipsychotic drugs</span><span class="headingEndMark"> — </span>Available evidence and our clinical experience support the efficacy of antipsychotic drugs for schizophrenia in patients with co-occurring SUD [<a href="#rid11">11-16</a>]; antipsychotic drugs are first-line treatment for schizophrenia with SUD as they are for schizophrenia without SUD. (See  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p class="headingAnchor" id="H163361042"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Large, well designed clinical trials of antipsychotic drugs have found little difference in efficacy between schizophrenia patients with substance use/SUD versus those without substance use/SUD. Some differences were seen in subgroup analyses and smaller trials.</p><p class="bulletIndent1"><span class="glyph">●</span>The Clinical Antipsychotics Trial of Intervention Effectiveness (CATIE) in the United States, randomly assigned 1432 patients with chronic schizophrenia to one of five first- or second-generation antipsychotic medications. Little difference was seen in symptom improvement, time to treatment discontinuation, or neurologic or metabolic side effects between patients who were concurrently using illicit drugs (55.1 percent) compared with those who were not (44.9 percent) [<a href="#rid17">17,18</a>]. A secondary analysis found that patients with moderate or severe drug use had poorer outcomes in symptoms of psychosis, depression, and quality of life compared with patients with no use or mild use [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The European First Episode Schizophrenia Trial (EUFEST) randomly assigned, without blinding, 498 first-episode schizophrenia patients to one of five first- or second-generation antipsychotic medications. After six months, no difference in psychopathology, overall neurocognitive functioning, or extrapyramidal symptoms (EPS) was found between patients with or without a concurrent SUD [<a href="#rid19">19</a>]. In subgroup analyses, patients with continuing, active substance use during treatment had a greater severity of positive symptoms compared with inactive and nonusers [<a href="#rid20">20</a>].</p><p></p><p>Early, small trials of antipsychotic drug treatment between schizophrenia patients with and without SUD largely found poorer results for patients with the co-occurring disorders across a wide range of outcomes, including general and cognitive functioning, adherence, relapse rates, unemployment, incarceration, homelessness, suicidality, violence, and rehospitalization [<a href="#rid16">16,21</a>]. More recent trials with smaller sample sizes have shown mixed results [<a href="#rid20">20,22</a>].</p><p>Secondary analysis of data from the EUFEST and CATIE antipsychotic trials found that substance use correlated significantly with nonadherence and discontinuation of antipsychotic treatment [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H2713754715"><span class="h3">Drug selection</span><span class="headingEndMark"> — </span>There is insufficient evidence to conclude that any one antipsychotic drug offers an advantage over others in controlling psychotic symptoms in schizophrenia patients with co-occurring SUD [<a href="#rid24">24</a>]. In the EUFEST and CATIE studies, no difference was found in effectiveness among numerous first- or second-generation antipsychotics in patients with schizophrenia and substance use [<a href="#rid17">17,18,20</a>].</p><p>Three smaller trials reported mixed results with <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> compared with other antipsychotics in this population:</p><p class="bulletIndent1"><span class="glyph">●</span>A trial of 61 patients with schizophrenia and alcohol use disorder found that <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> was more likely to reduce hospitalization rates compared with <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trial of 30 patients with schizophrenia and cannabis use found that <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> led to a greater reduction of positive symptoms compared with <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a>, but also produced more side effects and poorer compliance [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 31 patients with schizophrenia and cannabis use found no differences in symptoms or outcomes when patients were either switched to <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> or remained on their baseline antipsychotic [<a href="#rid27">27</a>].</p><p></p><p>In our clinical experience, long-acting, injectable antipsychotics can contribute to improved adherence and clinical outcomes in patients with schizophrenia and a co-occurring SUD [<a href="#rid24">24</a>]. They have shown mixed results in clinical trials [<a href="#rid28">28,29</a>]; however, these drugs are difficult to study in the unstable population that most needs them.</p><p class="headingAnchor" id="H4087631246"><span class="h3">Antipsychotic-substance interactions</span><span class="headingEndMark"> — </span>Interactions between abused substances and medications need consideration in the selection and dosing of antipsychotics in patients with schizophrenia and SUD. Smoking tobacco (rather than <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> intake more broadly) has been found to lower plasma levels of antipsychotic drugs [<a href="#rid30">30,31</a>]. The polycyclic aromatic hydrocarbons inhaled when smoking induce hepatic cytochrome P450 isoenzymes CYP1A1, 1A2, and 2E1, which effectively reduce plasma antipsychotic levels. <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">Olanzapine</a> and <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> are most affected among second-generation antipsychotics; <a class="drug drug_general" data-topicid="9252" href="/d/drug information/9252.html" rel="external">chlorpromazine</a>, <a class="drug drug_general" data-topicid="8467" href="/d/drug information/8467.html" rel="external">fluphenazine</a>, <a class="drug drug_general" data-topicid="9760" href="/d/drug information/9760.html" rel="external">perphenazine</a>, and <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a> among first-generation antipsychotics [<a href="#rid32">32,33</a>]. This effect has been linked to compensatory administration of increasing doses of antipsychotics [<a href="#rid33">33</a>].</p><p>When their smoking status changes, careful monitoring of schizophrenia patients’ antipsychotic side effects and psychotic symptoms is warranted; antipsychotic dose adjustments may be needed. Alcohol use in patients with schizophrenia is associated with reduced antipsychotic plasma levels; however, these patients generally do not require antipsychotic dose adjustments [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2123964952"><span class="h3">Side effects</span><span class="headingEndMark"> — </span>Analyses of data from observation studies and clinical trials of antipsychotic drug treatment have found mixed results in comparisons of rates of tardive dyskinesia (TD) and other EPS between schizophrenia with and without an SUD [<a href="#rid17">17,19,21,34-37</a>]. All patients receiving antipsychotics drugs should be closely monitored for TD and EPS. (See  <a class="medical medical_review" href="/d/html/4908.html" rel="external">"Tardive dyskinesia: Prevention, treatment, and prognosis"</a> and  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Side effect management'</a>.)</p><p class="headingAnchor" id="H4118925783"><span class="h1">SUBSTANCE USE DISORDER</span><span class="headingEndMark"> — </span>Substance use disorder (SUD) is commonly a chronic, relapsing condition requiring open ended, frequently life-long, continuous treatment. Continuing care for SUD is described in detail separately. (See  <a class="medical medical_review" href="/d/html/16754.html" rel="external">"Continuing care for addiction: Components and efficacy"</a> and  <a class="medical medical_review" href="/d/html/89215.html" rel="external">"Continuing care for addiction: Implementation"</a>.)</p><p>Based on research studies and our clinical experience, the presence of co-occurring schizophrenia can influence the choice of medications to treat the SUD, as described below. Pharmacotherapies for SUDs in patients <strong>without</strong><em> </em>schizophrenia, including dosing and adverse effects not addressed here, are discussed separately. (See  <a class="medical medical_review" href="/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults"</a> and  <a class="medical medical_review" href="/d/html/7796.html" rel="external">"Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/d/html/106878.html" rel="external">"Stimulant use disorder: Treatment overview"</a> and  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a> and  <a class="medical medical_review" href="/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p class="headingAnchor" id="H3777122931"><span class="h2">Antipsychotic drugs and SUDs</span><span class="headingEndMark"> — </span>While some clinical trials and secondary data analyses have found antipsychotic drugs to reduce substance use in schizophrenia patients with SUD, the findings (below) have been mixed, the studies have been methodologically limited, and the evidence is insufficient to recommend changes to antipsychotic drug prescribing in these patients [<a href="#rid24">24,38</a>].</p><p>Some of these studies suggest that <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> may have a greater effect on substance use compared with other antipsychotics. Properties unique to clozapine have been hypothesized to explain its possible superiority in reducing substance use [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Weak and rapidly dissociated blockade of dopamine receptors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alpha adrenergic blocking, which has been associated with substance use reduction [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amelioration of the mesocorticolimbic brain reward circuit deficiency that contributes to substance use disorder in patients with schizophrenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">Clozapine</a> may increase dopamine release in the prefrontal cortex and improve signal-detection capacity of the mesocorticolimbic dopamine-mediated circuitry.</p><p></p><p>Research on the influence of antipsychotic medications on substance use are described below in samples of schizophrenia patients with a specific SUD or a mix of SUDs:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed SUDs</strong> – Evidence for substance use reduction in samples of patients with mixed SUDs is mixed:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Clinical Antipsychotics Trial of Intervention Effectiveness (CATIE) study, described above, did not find differences in substance use reduction among four second-generation antipsychotic and a first-generation antipsychotic drugs [<a href="#rid42">42</a>]. (See <a class="local">'Antipsychotic drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An open trial of patients with schizophrenia and SUD treated with various antipsychotics suggested that <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> may be superior to other antipsychotics in reducing substance use. The study followed 223 schizophrenia patients from their initial six-month remission of substance use forward for 10 years [<a href="#rid43">43</a>]. Patients on clozapine at one year were much less likely to experience a relapse of the SUD compared with patients treated with other antipsychotics (8 versus 40 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An open trial of 1049 individuals with schizophrenia or schizoaffective disorder compared 257 participants taking <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> with 792 patients taking other antipsychotic medications [<a href="#rid44">44</a>]. Patients taking clozapine had lower odds of current alcohol (70.3 versus 82.4 percent), cannabis (19.7 versus 37.8 percent), and other drug use (7.1 versus 16.9 percent) despite similar lifetime odds.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tobacco smoking</strong> – It is not clear whether antipsychotic drugs reduce tobacco smoking in patients with schizophrenia. Secondary analyses of data from the CATIE study, described above, found antipsychotic drug treatment to be associated with reduced smoking [<a href="#rid42">42</a>]. Results from <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> trials were mixed [<a href="#rid45">45-48</a>]. As an example, in a clinical trial of 70 patients with treatment-refractory schizophrenia, the transition of 55 smokers from their baseline first-generation antipsychotic medication to clozapine was associated with reductions in cigarette smoking compared with prebaseline antipsychotic treatment [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alcohol use</strong> –<strong> </strong>There have been no clinical trials that directly test whether antipsychotic drugs reduce alcohol use in schizophrenia patients. Several uncontrolled trials and secondary analyses of clinical trial data have found associations between antipsychotics and reduced alcohol use in this population:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an analysis of data from CATIE, an 18-month clinical effectiveness trial described above, first- or second-generation antipsychotic treatment was associated with reduced alcohol use in 501 schizophrenia patients who used alcohol [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Earlier secondary analyses and uncontrolled trials with small samples reported that second-generation antipsychotics were associated with decreased alcohol use in schizophrenia patients [<a href="#rid49">49-51</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A secondary analysis of data from a three-year, uncontrolled study of 105 patients with schizophrenia or schizoaffective disorder and co-occurring SUD found <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> treatment to be associated with reduced alcohol use [<a href="#rid52">52</a>]. Nineteen schizophrenia patients treated with clozapine experienced decreases in alcohol abuse severity scores and in days of alcohol use (12.5 versus 54.1 drinking days) during periods on clozapine compared with periods off clozapine. At the end of the study, a greater proportion of patients on clozapine were in remission from alcohol use disorder for six months or longer compared with patients not taking clozapine (79 versus 33.7 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cannabis use</strong> – Small clinical trials found that patients treated with <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> did not reduce cannabis use compared with patients remaining on their current antipsychotic drug or treated with <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a> [<a href="#rid26">26,27</a>]. As an example, a clinical trial randomly assigned 31 antipsychotic-treated patients with schizophrenia and co-occurring cannabis use disorder to switch to clozapine or to stay on their current antipsychotic medication and be followed weekly for 12 weeks [<a href="#rid27">27</a>]. After 12 weeks, a statistically nonsignificant difference was seen between groups with patients receiving clozapine using less cannabis compared with the control group (mean of 11 versus 15.5 joints per week), suggesting that a well-powered trial is needed.</p><p></p><p class="bulletIndent1">A small study suggested <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> may decrease craving for cannabis compared with <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>. 38 patients with schizophrenia (30 with and 8 without co-occurring cannabis use disorder) and 20 healthy controls were randomized to antipsychotic treatment with clozapine or risperidone [<a href="#rid53">53</a>]. Brain response to cannabis-related images in areas implicated in substance-related cue reactivity such as the amygdala were measured using functional magnetic resonance imaging. Subjective craving was assessed using a self-report questionnaire. At baseline, patients with comorbid cannabis use disorder evinced greater subjective craving and greater activation in response to cannabis-related images compared with patients without comorbid cannabis use and healthy controls. Clozapine-treated patients with co-occurring cannabis use disorder reported a greater reduction in craving and showed a larger decrease in amygdala activation during cannabis-related images compared with risperidone-treated patients with cannabis use disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cocaine use</strong> – There are no clinical trials comparing the efficacy of antipsychotic drugs with placebo in reducing cocaine use. Small clinical trials found mixed results in comparing the efficacy of first-generation versus second-generation antipsychotics in reducing cocaine use [<a href="#rid11">11,12,54</a>]. As an example, a clinical trial compared <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> with <a class="drug drug_general" data-topicid="8516" href="/d/drug information/8516.html" rel="external">haloperidol</a> in 24 patients with schizophrenia and cocaine abuse, finding no difference in positive drug screens. Craving for cocaine was rated as lower by patients receiving haloperidol [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H2041393684"><span class="h2">Tobacco use disorder</span><span class="headingEndMark"> — </span>For schizophrenia patients attempting to stop smoking tobacco, we suggest first-line treatment with <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT) in combination with behaviorally oriented psychosocial treatment rather than other medications. <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">Bupropion</a> and <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a> are reasonable alternatives to NRT in patients without suicidal ideation or a history of suicidal behavior. Pharmacotherapy appears to play a more critical role for smokers with schizophrenia than in other smokers, increasing the odds of quitting by a factor of four- to fivefold, likely because of the low quit rate with behavioral treatment alone [<a href="#rid55">55</a>]. Maintenance pharmacotherapy also appears to differentially improve relapse rates for smokers with schizophrenia.</p><p>Reports submitted to the US Food and Drug Administration (FDA) suggesting an association between the latter drugs and neuropsychiatric adverse events have not been borne out in subsequent research. There are no controlled trial data in smokers with psychiatric illness in general or with schizophrenia that have shown increased neuropsychiatric adverse events with <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a> or <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> compared with placebo or NRT [<a href="#rid55">55</a>]. (See <a class="local">'Safety'</a> below.)</p><p>Schizophrenia patients attempting to stop smoking, whether treated with smoking cessation medications or not, should be closely monitored for emerging depression, suicidality, or exacerbation of existing psychiatric and extrapyramidal symptoms. Patients should be advised to stop taking medications if changes in thinking or behavior develop. Some clinicians take a more conservative approach with <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a>, not prescribing the drug to patients with unstable or prominent depressive symptoms or those at risk for suicidal behavior.</p><p class="headingAnchor" id="H184017988"><span class="h3">Efficacy</span></p><p class="headingAnchor" id="H251942271"><span class="h4">Comparative and combination smoking cessation medication studies</span><span class="headingEndMark"> — </span>Systematic reviews and meta-analyses have found that the smoking cessation medications <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> are effective in patients with serious mental illness including schizophrenia [<a href="#rid56">56,57</a>]. There were no differences between groups in tolerability. No trials were found that compared <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> replacement therapies with placebo. As an example, a 2017 26-week trial randomly assigned 42 patients with DSM-IV diagnoses of schizophrenia and tobacco use disorder to either treatment as usual or combined treatment initiated with bupropion (150 mg twice daily), nicotine patch (21 mg), nicotine lozenges (2 and 4 mg), weekly group cognitive-behavioral therapy (CBT), and in some cases biweekly home visits. Combined medication and CBT resulted in a greater reduction in cigarettes smoked and a greater seven-day point prevalence rate of abstinence compared with treatment as usual [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H3355061912"><span class="h4">Varenicline</span><span class="headingEndMark"> — </span>Clinical trials have found <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a>, a nicotinic receptor partial agonist, to increase smoking cessation rates in schizophrenia patients (below); reports of increased suicidal ideation and attempts associated with the drug have not been borne out in meta-analyses of available data or a large, rigorous trial [<a href="#rid59">59-62</a>]. As an example, a 2013 meta-analysis of two clinical trials with a total of 137 patients with schizophrenia found an increased smoking cessation rate with varenicline compared with placebo (risk ratio = 4.74, 95% CI 1.34-16.71) [<a href="#rid45">45</a>]. Improved cessation rates with varenicline have been found in patients with and without severe mental illness.</p><p class="headingAnchor" id="H1175767005"><span class="h4">Bupropion</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">Bupropion</a>, which modulates dopamine and noradrenergic tone and may inhibit nicotinic acetylcholine receptors [<a href="#rid59">59,63</a>],<strong> </strong>appears to be efficacious for smoking cessation in patients with schizophrenia. A systematic review and meta-analysis of seven clinical trials with a total of 340 schizophrenia patients found higher cessation rates in patients receiving bupropion compared with patients receiving placebo at the end of treatment (risk ratio = 3.03; 95% CI 1.69-5.42) and at six months [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H172316265"><span class="h4">Nicotine replacement therapy</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT) for smoking cessation in the general population is well established and has been reported in patients with schizophrenia [<a href="#rid59">59</a>], but available research is insufficient to draw conclusions about its efficacy for smoking cessation in patients with schizophrenia [<a href="#rid45">45</a>]. In our clinical experience, these agents are effective in reducing symptoms of nicotine withdrawal in schizophrenia, with consistency across delivery systems (transdermal patch, gum, lozenges, nasal spray, and inhalation).</p><p>Nicotinic agents may have positive effects on concentration and cognition in schizophrenia, having been implicated in studies of mechanisms underlying improvements [<a href="#rid45">45,64</a>]. NRT does not affect antipsychotic drug levels; the effect of smoking tobacco on plasma levels is described above [<a href="#rid30">30,31</a>]. (See <a class="local">'Antipsychotic-substance interactions'</a> above and  <a class="medical medical_review" href="/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults", section on 'Nicotine replacement therapy'</a>.)</p><p class="headingAnchor" id="H4127403310"><span class="h3">Safety</span><span class="headingEndMark"> — </span>Preliminary studies of the effects of <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> and smoking cessation agents on antipsychotic-induced extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) have yielded conflicting findings. Studies of tobacco smoking and smoking cessation in schizophrenia patients receiving antipsychotics have found both increased and decreased risk and severity of EPS and TD. Apart from direct effects on nicotinic receptors, smoking can induce metabolism and lower plasma levels of antipsychotic drugs [<a href="#rid65">65-69</a>]. Patients should be advised of possible effects and monitored for changes in involuntary movements when altering smoking habits or initiating smoking cessation treatment.</p><p>Early reports of newly emergent psychiatric symptoms raised questions about the safety of <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> for smoking cessation in patients with mental disorders, but subsequent research has supported their use in patients whose disorders are stable.</p><p>A 2009 review of adverse events submitted to the FDA raised concerns about a possible association between the medications and the emergence of depression, suicidal ideation, and/or suicidal behavior [<a href="#rid70">70,71</a>]. Subsequent reviews and meta-analyses of clinical trials comparing these drugs to placebo did not find associations between the smoking-cessation medications and emergence or exacerbation of psychiatric symptoms or suicidal/self-injurious behavior [<a href="#rid45">45,60,72,73</a>]. As an example, a 2015 meta-analysis of 39 randomized trials comparing <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a> with placebo in over 10,000 participants [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults", section on 'Varenicline'</a> and  <a class="medical medical_review" href="/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults", section on 'Bupropion'</a>.)</p><p>A subsequent, large clinical trial found that the rate of psychiatric adverse events in smokers receiving <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a> or <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> did not exceed the rate in patients receiving placebo by a statistically significant extent [<a href="#rid59">59</a>]. The trial randomly assigned 8144 motivated adult smokers, approximately half with clinically stable mental disorders (10 percent with schizophrenia or schizoaffective disorder), to receive varenicline, bupropion, transdermal <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a>, or placebo for 12 weeks. All patients received brief cessation counseling. Patients with mental disorders were more likely to experience neuropsychiatric adverse events (including moderate-to-severe anxiety, depression, agitation, or hostility) during the treatment period compared with patients without mental disorders (5.8 versus 2.1 percent), but among patients with mental disorders, the rate of events did not differ for patients assigned to varenicline (risk difference = 1.59, 95% CI -0.42 to 3.59) or bupropion (1.78, 95% CI -0.24 to 3.81) rather than placebo. Rates of smoking abstinence were higher with all three drugs compared with placebo, and with varenicline compared with bupropion and transdermal nicotine, in both patients with and without mental disorders. The trial supports the use of varenicline and bupropion in smokers with stable mental disorders.</p><p>To separate the adverse <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> withdrawal effects of smoking cessation itself from adverse reactions to pharmacotherapy, some authors have suggested using the flexible quit approach outlined in the FDA approved labeling for <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a> [<a href="#rid55">55</a>]. This requires separating initiation of cessation pharmacotherapy from the target quit date by four weeks, thus allowing assessment and adjustment of tolerability to treatment apart from smoking/nicotine withdrawal effects.</p><p class="headingAnchor" id="H292187158"><span class="h2">Alcohol use disorder</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a> – Based on our clinical experience, evidence from open trials, and randomized controlled studies involving diverse psychiatric populations [<a href="#rid75">75</a>], naltrexone appears to be effective and safe in inpatients with co-occurring schizophrenia and alcohol use disorder [<a href="#rid76">76,77</a>]. As an example, a 12-week randomized controlled trial of 31 patients with co-occurring schizophrenia and alcohol dependence found that patients treated with naltrexone experienced fewer alcohol cravings, drinking days, and heavy drinking days compared with patients treated with placebo [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p></p><p class="bulletIndent1">Clinical studies are insufficient to draw conclusions on the efficacy and safety of other medications for alcohol use disorder in this population:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9379" href="/d/drug information/9379.html" rel="external">Disulfiram</a> – A retrospective study of disulfiram for alcohol abuse/dependence in 33 patients with a severe mental illness (70 percent with schizophrenia) found that 64 percent attained remission of at least one year [<a href="#rid79">79</a>]. Seventy-six percent of the sample reported drinking while taking the medication; 28 percent reported experiencing negative reactions to alcohol. The drug was mostly well tolerated at doses of 250 mg/day; 21 percent of patients reported side effects, consisting mainly of upset stomach and skin rash. Higher doses, eg, 1000 mg/day, have been associated with agitation and exacerbation of psychotic symptoms.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9379" href="/d/drug information/9379.html" rel="external">Disulfiram</a> inhibits dopamine beta-hydroxylase, the rate limiting enzyme in the conversion of dopamine to norepinephrine, and may increase dopamine levels in the brain [<a href="#rid76">76</a>]. Patients with schizophrenia who are treated with disulfiram should be screened for their capacity to abstain from alcohol, and should be monitored closely for drug reactions, SUD treatment response, and exacerbation of psychosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9218" href="/d/drug information/9218.html" rel="external">Acamprosate</a> – Randomized clinical trials have had mixed findings on the influence of acamprosate on alcohol use among patients with schizophrenia and DSM-IV alcohol dependence:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized clinical trial of 23 recently abstinent patients with alcohol dependence and comorbid schizophrenia, schizoaffective disorder, or psychosis not otherwise specified compared <a class="drug drug_general" data-topicid="9218" href="/d/drug information/9218.html" rel="external">acamprosate</a> with placebo [<a href="#rid80">80</a>]. Participants in both groups decreased their drinking during medication treatment; no difference in alcohol use was found between the two groups. The medication was well tolerated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized clinical trial divided 36 patients with schizophrenia and alcohol use disorder into three groups: <a class="drug drug_general" data-topicid="9218" href="/d/drug information/9218.html" rel="external">acamprosate</a> 999 mg daily, <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> 50 mg daily, and counseling focused on addictive behavior [<a href="#rid81">81</a>]. Over the 24-week treatment period, although both naltrexone and acamprosate had significant effects on maintenance of abstinence, acamprosate produced a larger effect, adding an additional 23.6 days sober.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">Baclofen</a> – An uncontrolled trial of baclofen in 10 patients found mixed results [<a href="#rid82">82</a>].</p><p></p><p>Use of medications in the treatment of alcohol use disorder, including dosing and adverse effects, is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p class="headingAnchor" id="H3012320001"><span class="h2">Cannabis use disorder</span><span class="headingEndMark"> — </span>There are no medications with demonstrated efficacy in patients with cannabis use disorder and schizophrenia. A meta-analysis concluded that existing trials are limited and inconclusive due to their small number and size [<a href="#rid83">83</a>].</p><p>Clinical trials of medications for noncomorbid cannabis use disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/7796.html" rel="external">"Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"</a>.)</p><p class="headingAnchor" id="H225803432"><span class="h2">Cocaine use disorder</span><span class="headingEndMark"> — </span>Two reports found treatment with tricyclic antidepressants to be associated with reduced cocaine use in small samples [<a href="#rid84">84,85</a>]. As an example, a nonrandomized, unblinded trial of patients with schizophrenia and DSM-IV cocaine abuse compared 12 patients who were treated with antipsychotics and <a class="drug drug_general" data-topicid="9329" href="/d/drug information/9329.html" rel="external">desipramine</a> with 25 patients treated with antipsychotics and placebo, finding that patients treated with desipramine had fewer urinalyses positive for cocaine during the last six weeks of the trial compared with placebo (20 versus 50 percent) [<a href="#rid84">84</a>]. Clinical trials of medications for noncomorbid cocaine use disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/106878.html" rel="external">"Stimulant use disorder: Treatment overview"</a>.)</p><p class="headingAnchor" id="H1898702757"><span class="h2">Opioid use disorder</span></p><p class="headingAnchor" id="H2891599877"><span class="h3">Opioid agonists</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> and <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, which provide effective maintenance treatment of opioid use disorder [<a href="#rid38">38,86,87</a>], have not been studied for opioid use disorder in patients with schizophrenia. In our clinical experience, however, the medications have been used safely and effectively in patients with the dual disorders. Medication treatment of noncomorbid opioid use disorder is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a>.)</p><p class="headingAnchor" id="H1144310637"><span class="h3">Opioid antagonists</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a> has received little study in the treatment of opioid use disorder in patients with schizophrenia; it has been used safely and effectively in patients with noncomorbid opioid use disorder and to treat alcohol use disorder in patients with schizophrenia. (See <a class="local">'Alcohol use disorder'</a> above and  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Naltrexone: Opioid antagonist'</a>.)</p><p class="headingAnchor" id="H2545156067"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113643.html" rel="external">"Society guideline links: Opioid use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114814.html" rel="external">"Society guideline links: Benzodiazepine use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114306.html" rel="external">"Society guideline links: Alcohol use disorders and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115010.html" rel="external">"Society guideline links: Stimulant use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114308.html" rel="external">"Society guideline links: Cannabis use disorder and withdrawal"</a>.)</p><p class="headingAnchor" id="H732509748"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest multimodal, integrated care for patients with co-occurring schizophrenia and substance use disorder (SUD) rather than separate care for each disorder or sequential care (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Multimodal care generally includes pharmacotherapy and one or more psychosocial interventions. In integrated care, the same clinician or team treats both conditions, while in parallel care the mental disorder and SUD are treated by different clinicians. When integrated treatment is not available, clinicians treating the co-occurring disorders should closely coordinate care. (See <a class="local">'Integrated treatment'</a> above and  <a class="medical medical_review" href="/d/html/89630.html" rel="external">"Co-occurring schizophrenia and substance use disorder: Psychosocial interventions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SUDs can exacerbate psychotic symptoms directly through the psychoactive effects of substances, or indirectly by pharmacokinetically lowering antipsychotic plasma levels or by contributing to poor patient adherence to treatment. (See <a class="local">'Schizophrenia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend treatment of schizophrenia symptoms, including SUD-induced exacerbations, with an antipsychotic medication rather than other primary medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Schizophrenia'</a> above and  <a class="medical medical_review" href="/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a> and  <a class="medical medical_review" href="/d/html/14773.html" rel="external">"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"</a> and  <a class="medical medical_review" href="/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest treatment of schizophrenia in patients with SUD who are nonadherent to antipsychotic medication with a long-acting injectable antipsychotic rather than a daily antipsychotic taken orally (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Antipsychotic drugs'</a> above and  <a class="medical medical_review" href="/d/html/15250.html" rel="external">"Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tobacco smoking has been found to lower antipsychotic plasma levels in schizophrenia patients. Careful monitoring of patients’ antipsychotic side effects and psychotic symptoms is warranted when their smoking status changes; antipsychotic dose adjustments may be needed. Alcohol use in patients with schizophrenia is also associated with reduced antipsychotic plasma levels; however, these patients generally do not require antipsychotic dose adjustments. (See <a class="local">'Antipsychotic-substance interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While some clinical trials and secondary data analyses have found antipsychotic drugs to reduce substance use in schizophrenia patients with SUD, the findings have been mixed, the studies have been methodologically limited, and the evidence is insufficient to recommend changes to antipsychotic drug prescribing in these patients. (See <a class="local">'Antipsychotic drugs and SUDs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For schizophrenia patients attempting to stop smoking tobacco, we suggest first-line treatment with <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT) in combination with behaviorally oriented psychosocial treatment rather than other medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">Bupropion</a> and <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a> are reasonable alternative to NRT in stable patients without suicidal ideation or a history of suicidal behavior.</p><p></p><p class="bulletIndent1">Schizophrenia patients attempting to stop smoking and those treated with smoking cessation medication should be closely monitored for emerging depression, suicidality, or exacerbation of existing psychiatric or extrapyramidal symptoms. Some clinicians take a more conservative approach with <a class="drug drug_general" data-topicid="10339" href="/d/drug information/10339.html" rel="external">varenicline</a>, not prescribing the drug to patients with prominent depressive symptoms. (See <a class="local">'Tobacco use disorder'</a> above and  <a class="medical medical_review" href="/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although research is limited, in our clinical experience, the following agents can be used safely and effectively for the corresponding SUD in patients with co-occurring schizophrenia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">Naltrexone</a> in alcohol use disorder. (See <a class="local">'Alcohol use disorder'</a> above and  <a class="medical medical_review" href="/d/html/108891.html" rel="external">"Alcohol use disorder: Treatment overview"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a>, <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, or <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> in opioid use disorder. (See <a class="local">'Opioid use disorder'</a> above and  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harv Rev Psychiatry 2009; 17:24.</a></li><li><a class="nounderline abstract_t">Fryers T, Melzer D, Jenkins R, Brugha T. The distribution of the common mental disorders: social inequalities in Europe. Clin Pract Epidemiol Ment Health 2005; 1:14.</a></li><li><a class="nounderline abstract_t">Scott KM, Al-Hamzawi AO, Andrade LH, et al. Associations between subjective social status and DSM-IV mental disorders: results from the World Mental Health surveys. JAMA Psychiatry 2014; 71:1400.</a></li><li><a class="nounderline abstract_t">Brown T, Platt S, Amos A. Equity impact of European individual-level smoking cessation interventions to reduce smoking in adults: a systematic review. Eur J Public Health 2014; 24:551.</a></li><li><a class="nounderline abstract_t">Bull ER, Dombrowski SU, McCleary N, Johnston M. Are interventions for low-income groups effective in changing healthy eating, physical activity and smoking behaviours? A systematic review and meta-analysis. BMJ Open 2014; 4:e006046.</a></li><li><a class="nounderline abstract_t">Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005; 11:315.</a></li><li><a class="nounderline abstract_t">Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull 2000; 26:105.</a></li><li><a class="nounderline abstract_t">Hunt GE, Siegfried N, Morley K, et al. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2013; :CD001088.</a></li><li class="breakAll">Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series, National Academies Press, Washington DC 2006. p.210.</li><li><a class="nounderline abstract_t">De Witte NA, Crunelle CL, Sabbe B, et al. Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review. Eur Addict Res 2014; 20:105.</a></li><li><a class="nounderline abstract_t">Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 2006; 26:9.</a></li><li><a class="nounderline abstract_t">Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005; 193:379.</a></li><li><a class="nounderline abstract_t">Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002; 54:253.</a></li><li><a class="nounderline abstract_t">Sevy S, Robinson DG, Sunday S, et al. Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Res 2011; 188:310.</a></li><li><a class="nounderline abstract_t">Brunetti M, Di Tizio L, Dezi S, et al. Aripiprazole, alcohol and substance abuse: a review. Eur Rev Med Pharmacol Sci 2012; 16:1346.</a></li><li><a class="nounderline abstract_t">Kerfoot KE, Rosenheck RA, Petrakis IL, et al. Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res 2011; 132:177.</a></li><li><a class="nounderline abstract_t">Swartz MS, Wagner HR, Swanson JW, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res 2008; 100:39.</a></li><li class="breakAll">Rheimerr F, Swartz MS, Olsen JL. Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome. In: Antipsychotic Trials in Schizophrenia: The CATIE Project, Stroup TS, Lieberman JA (Eds), Cambridge University Press, New York 2006. p.189.</li><li><a class="nounderline abstract_t">Wobrock T, Falkai P, Schneider-Axmann T, et al. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res 2013; 147:132.</a></li><li><a class="nounderline abstract_t">Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371:1085.</a></li><li><a class="nounderline abstract_t">Lybrand J, Caroff S. Management of schizophrenia with substance use disorders. Psychiatr Clin North Am 2009; 32:821.</a></li><li><a class="nounderline abstract_t">Pelayo-Terán JM, Diaz FJ, Pérez-Iglesias R, et al. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol Med 2014; 44:37.</a></li><li><a class="nounderline abstract_t">Czobor P, Van Dorn RA, Citrome L, et al. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 2015; 25:1158.</a></li><li><a class="nounderline abstract_t">Azorin JM, Simon N, Adida M, Belzeaux R. Pharmacological treatment of schizophrenia with comorbid substance use disorder. Expert Opin Pharmacother 2016; 17:231.</a></li><li><a class="nounderline abstract_t">Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:984.</a></li><li><a class="nounderline abstract_t">Schnell T, Koethe D, Krasnianski A, et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict 2014; 23:308.</a></li><li><a class="nounderline abstract_t">Brunette MF, Dawson R, O'Keefe CD, et al. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn 2011; 7:50.</a></li><li><a class="nounderline abstract_t">Green AI, Brunette MF, Dawson R, et al. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry 2015; 76:1359.</a></li><li><a class="nounderline abstract_t">Leatherman SM, Liang MH, Krystal JH, et al. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. J Nerv Ment Dis 2014; 202:13.</a></li><li><a class="nounderline abstract_t">Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand 1991; 84:272.</a></li><li><a class="nounderline abstract_t">Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 1992; 8:93.</a></li><li><a class="nounderline abstract_t">Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001; 15:469.</a></li><li><a class="nounderline abstract_t">Jin Y, Pollock BG, Coley K, et al. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 2010; 50:73.</a></li><li><a class="nounderline abstract_t">Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990; 16:57.</a></li><li><a class="nounderline abstract_t">Potvin S, Pampoulova T, Mancini-Marië A, et al. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006; 77:796.</a></li><li><a class="nounderline abstract_t">Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005; 80:33.</a></li><li><a class="nounderline abstract_t">Zhornitsky S, Stip E, Pampoulova T, et al. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Mov Disord 2010; 25:2188.</a></li><li><a class="nounderline abstract_t">Bennett ME, Bradshaw KR, Catalano LT. Treatment of substance use disorders in schizophrenia. Am J Drug Alcohol Abuse 2017; 43:377.</a></li><li><a class="nounderline abstract_t">Jones RM, Lichtenstein P, Grann M, et al. Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients. J Clin Psychiatry 2011; 72:775.</a></li><li><a class="nounderline abstract_t">Khokhar JY, Chau DT, Dawson R, Green AI. Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan. Drug Alcohol Depend 2015; 152:277.</a></li><li><a class="nounderline abstract_t">Shorter D, Nielsen DA, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation. Eur Neuropsychopharmacol 2013; 23:1401.</a></li><li><a class="nounderline abstract_t">Mohamed S, Rosenheck RA, Lin H, et al. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. J Nerv Ment Dis 2015; 203:486.</a></li><li><a class="nounderline abstract_t">Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006; 32:637.</a></li><li><a class="nounderline abstract_t">Siskind DJ, Harris M, Phillipou A, et al. Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. Epidemiol Psychiatr Sci 2017; 26:325.</a></li><li><a class="nounderline abstract_t">Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013; :CD007253.</a></li><li><a class="nounderline abstract_t">McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 46:125.</a></li><li><a class="nounderline abstract_t">de Leon J, Diaz FJ, Josiassen RC, et al. Does clozapine decrease smoking? Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:757.</a></li><li><a class="nounderline abstract_t">Wu BJ, Lan TH. Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders. Eur Arch Psychiatry Clin Neurosci 2017; 267:63.</a></li><li><a class="nounderline abstract_t">Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005; 25:363.</a></li><li><a class="nounderline abstract_t">Huang CC. Risperdal reduces alcohol use in dual disabled schizophrenia patients. Eur Neuropsychopharmacol 1996; 6:43.</a></li><li><a class="nounderline abstract_t">Weisman RL. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. Int J Psychiatry Med 2003; 33:85.</a></li><li><a class="nounderline abstract_t">Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26:441.</a></li><li><a class="nounderline abstract_t">Machielsen MWJ, Veltman DJ, van den Brink W, de Haan L. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophr Res 2018; 194:32.</a></li><li><a class="nounderline abstract_t">Beresford T, Buchanan J, Thumm EB, et al. Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. J Clin Psychopharmacol 2017; 37:657.</a></li><li><a class="nounderline abstract_t">Cather C, Pachas GN, Cieslak KM, Evins AE. Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations. CNS Drugs 2017; 31:471.</a></li><li><a class="nounderline abstract_t">McGinty EE, Baller J, Azrin ST, et al. Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review. Schizophr Bull 2016; 42:96.</a></li><li><a class="nounderline abstract_t">Roberts E, Eden Evins A, McNeill A, Robson D. Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. Addiction 2016; 111:599.</a></li><li><a class="nounderline abstract_t">Brody AL, Zorick T, Hubert R, et al. Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial. Nicotine Tob Res 2017; 19:68.</a></li><li><a class="nounderline abstract_t">Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387:2507.</a></li><li><a class="nounderline abstract_t">Cerimele JM, Durango A. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. J Clin Psychiatry 2012; 73:e1039.</a></li><li><a class="nounderline abstract_t">Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 2014; 311:145.</a></li><li><a class="nounderline abstract_t">Smith RC, Amiaz R, Si TM, et al. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. PLoS One 2016; 11:e0143490.</a></li><li><a class="nounderline abstract_t">Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295:321.</a></li><li><a class="nounderline abstract_t">Mackowick KM, Barr MS, Wing VC, et al. Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems. Prog Neuropsychopharmacol Biol Psychiatry 2014; 52:79.</a></li><li><a class="nounderline abstract_t">Toffey BA, Rabin M, Kurlan R. Withdrawal-Emergent Dyskinesias following Varenicline Therapy. Open Neurol J 2015; 9:7.</a></li><li><a class="nounderline abstract_t">Dalack GW, Becks L, Hill E, et al. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999; 21:195.</a></li><li><a class="nounderline abstract_t">Caroff SN, Walker P, Campbell C, et al. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry 2007; 68:410.</a></li><li><a class="nounderline abstract_t">Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993; 34:713.</a></li><li><a class="nounderline abstract_t">Quik M, Bordia T, Zhang D, Perez XA. Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders. Int Rev Neurobiol 2015; 124:247.</a></li><li class="breakAll">The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Drug Safety Newsletter 2009; 2:1. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/ucm107318.pdf (Accessed on September 20, 2011).</li><li><a class="nounderline abstract_t">Moore TJ, Furberg CD, Glenmullen J, et al. Suicidal behavior and depression in smoking cessation treatments. PLoS One 2011; 6:e27016.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry 2013; 170:1460.</a></li><li><a class="nounderline abstract_t">Wu IH, Chen H, Bordnick P, et al. Comparison of Suicide Attempts/Behaviors Following Smoking Cessation Treatments Among Schizophrenic Smokers. Arch Psychiatr Nurs 2017; 31:62.</a></li><li><a class="nounderline abstract_t">Thomas KH, Martin RM, Knipe DW, et al. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015; 350:h1109.</a></li><li><a class="nounderline abstract_t">Sawicka M, Tracy DK. Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review. Ther Adv Psychopharmacol 2017; 7:211.</a></li><li><a class="nounderline abstract_t">Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 2006; 32:644.</a></li><li><a class="nounderline abstract_t">Batki SL, Dimmock JA, Meszaros ZS, et al. Extended-release naltrexone for alcohol dependence in patients with serious mental illness. Alcohol Clin Exp Res 2010; 34:176A.</a></li><li><a class="nounderline abstract_t">Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004; 172:291.</a></li><li><a class="nounderline abstract_t">Mueser KT, Noordsy DL, Fox L, Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003; 12:242.</a></li><li><a class="nounderline abstract_t">Ralevski E, O'Brien E, Jane JS, et al. Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. J Dual Diagn 2011; 7:64.</a></li><li><a class="nounderline abstract_t">Bratu ER, Sopterean GA. Comparison of the efficacies of naltrexone and acamprosate in the treatment of patients with chronic schizophrenia who are alcohol dependent. Eur Neuropsychopharmacol 2014; 24:S71.</a></li><li><a class="nounderline abstract_t">Schöpf J, Hucker H. Baclofen in the treatment of schizophrenia: a pilot study. Pharmakopsychiatr Neuropsychopharmakol 1977; 10:89.</a></li><li><a class="nounderline abstract_t">McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database Syst Rev 2014; :CD004837.</a></li><li><a class="nounderline abstract_t">Ziedonis D, Richardson T, Lee E, et al. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 1992; 28:309.</a></li><li><a class="nounderline abstract_t">Siris SG, Mason SE, Bermanzohn PC, et al. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull 1993; 29:127.</a></li><li><a class="nounderline abstract_t">Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; :CD002209.</a></li><li><a class="nounderline abstract_t">Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; :CD002207.</a></li></ol></div><div id="topicVersionRevision">Topic 106146 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19205964" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143042" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The distribution of the common mental disorders: social inequalities in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25354080" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Associations between subjective social status and DSM-IV mental disorders: results from the World Mental Health surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24891458" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Equity impact of European individual-level smoking cessation interventions to reduce smoking in adults: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25432903" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Are interventions for low-income groups effective in changing healthy eating, physical activity and smoking behaviours? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16184072" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755672" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Psychosocial approaches to dual diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092525" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Psychosocial interventions for people with both severe mental illness and substance misuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092525" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Psychosocial interventions for people with both severe mental illness and substance misuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24192558" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415698" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920378" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11950550" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21636134" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23104650" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Aripiprazole, alcohol and substance abuse: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21872443" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Substance use and schizophrenia: adverse correlates in the CATIE study sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191383" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191383" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23537477" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374841" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19944886" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Management of schizophrenia with substance use disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23461899" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26004980" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26635059" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pharmacological treatment of schizophrenia with comorbid substance use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18262321" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628830" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25914610" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26302441" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24375206" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1950628" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Alcohol abuse in chronic schizophrenics: implications for management in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1360812" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Smoking and schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524025" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19843655" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1970451" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tardive dyskinesia in psychiatric patients with substance use disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16705205" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16171976" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20669315" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27715317" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of substance use disorders in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21733478" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979645" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849431" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pharmacogenetic randomized trial for cocaine abuse: disulfiram andα1A-adrenoceptor gene variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26075840" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16782758" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27426892" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450574" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Interventions for smoking cessation and reduction in individuals with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10394482" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Smoking and therapeutic response to clozapine in patients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15951089" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Does clozapine decrease smoking?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26310877" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16012280" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Aripiprazole in schizophrenia with cocaine dependence: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Risperdal reduces alcohol use in dual disabled schizophrenia patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12906345" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10885642" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28351544" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28984746" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28550660" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26221050" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26594837" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27613888" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116918" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22967780" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399553" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26730716" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10991997" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Bupropion is a nicotinic antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23871750" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26106454" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Withdrawal-Emergent Dyskinesias following Varenicline Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10432467" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17388711" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904833" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26472532" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26472532" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22073240" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Suicidal behavior and depression in smoking cessation treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24030388" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Varenicline, smoking cessation, and neuropsychiatric adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28104060" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Comparison of Suicide Attempts/Behaviors Following Smoking Cessation Treatments Among Schizophrenic Smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25767129" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28959434" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16887890" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Extended-release naltrexone for alcohol dependence in patients with serious mental illness</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14634716" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12851020" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Disulfiram treatment for alcoholism in severe mental illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26954912" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Comparison of the efficacies of naltrexone and acamprosate in the treatment of patients with chronic schizophrenia who are alcohol dependent</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/360234" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Baclofen in the treatment of schizophrenia: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25314586" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cannabis and schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1480735" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Adjunctive desipramine in the treatment of cocaine abusing schizophrenics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8378506" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588333" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500948" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
